Investigational drug · Phase 2
GV101
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Friedreich's Ataxia, Weight Management.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "GV101"
First trial start
2025
Jun 30, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GV101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Friedreich's Ataxia
- Weight Management
Approved drugs for the same conditions: Cardiovascular and metabolic · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "GV101" as an intervention, largest first.
- GV101 in Healthy Obese ParticipantsPivotal-lookingCompleted
Graviton Bioscience CorporationIndustry
NCT06979505 · 131 participants · Start Jun 30, 2025 · Primary completion Jan 28, 2026
Drug: GV101; GV101 placebo · For: Weight Management
Sites: Guntersville, Alabama; Tucson, Arizona; Montclair, California · 20 sites in all
- GV101 for Friedreich's Ataxia (FA) TreatmentNot yet recruiting
Graviton Bioscience CorporationIndustry
NCT07870590 · 48 participants (planned) · Start Nov 2026 · Primary completion Jul 2027
Drug: GV101; Placebo · For: Friedreich's Ataxia
Sites: Eatontown, New Jersey
Graviton Bioscience CorporationIndustry
NCT05068947 · 16 participants · Start Sep 10, 2021 · Primary completion Oct 22, 2021
Drug: GV101; Placebo · For: Phase 1
Sites: Hialeah, Florida
Newest research
PubMed records naming it or its code names, newest first.
- Role of ROCK2 inhibitors in the treatment of chronic graft-versus-host disease.
Ngo D, Tinajero J, Otoukesh S, et al. · Expert Opin Investig Drugs 2025
- Selectivity matters: selective ROCK2 inhibitor ameliorates established liver fibrosis via targeting inflammation, fibrosis, and metabolism.
Zanin-Zhorov A, Chen W, Moretti J, et al. · Commun Biol 2023
- Functional characterization of 1-aminocyclopropane-1-carboxylic acid oxidase gene in Arabidopsis thaliana and its potential in providing flood tolerance.
Ramadoss N, Gupta D, Vaidya BN, et al. · Biochem Biophys Res Commun 2018
- The bacterial hemoglobin from Vitreoscilla can support the aerobic growth of Escherichia coli lacking terminal oxidases.
Dikshit RP, Dikshit KL, Liu YX, et al. · Arch Biochem Biophys 1992
- Studies with a bivalent infectious bronchitis killed virus vaccine.
Finney PM, Box PG, Holmes HC · Avian Pathol 1990
Also in development for Friedreich's Ataxia
- VatiquinonePTC743Phase 33 trials
PTC Therapeutics · Friedreich's Ataxia, Friedreich Ataxia, Inherited Mitochondrial Disease
- NomlabofuspCTI-1601Phase 32 trials
Larimar Therapeutics, Inc. · Friedreich Ataxia, Friedreich's Ataxia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.